证券代码：002513 证券简称：蓝丰生化 公告编号：2025-010 江苏蓝丰生物化工股份有限公司 第七届监事会第十八次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届监事会第十八 次会议于 2025 年 4 月 27 日以通讯表决方式召开。本次会议通知已于 2025 年 4 月 17 日以微信、电子邮件的方式通知全体监事。本次会议由公司监事会主席韩 宜辰先生主持，应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开及 表决程序符合《公司法》和《公司章程》的规定，合法有效。 1 二、监事会会议审议情况 （一）审议通过《关于公司 2024 年度监事会工作报告的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 具体详见 2025 年 4 月 29 日刊登在公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）上的公告。 本议案尚需提交公司股东大会审议通过。 （二）审议通过《关于公司 2024 年年度报告全文及摘要的议案》 经审核，监事会认为公 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-009 江苏蓝丰生物化工股份有限公司 第七届董事会第二十三次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第二十 三次会议于 2025 年 4 月 27 日以通讯表决方式召开。本次会议已于 2025 年 4 月 17 日以微信、电子邮件的方式通知全体董事。本次会议由公司董事长郑旭先生 主持，应出席董事 8 人，实际出席董事 8 人，监事和高管列席会议。本次会议的 召集、召开及表决程序符合《公司法》和《公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于公司 2024 年度董事会工作报告的议案》 表决结果：8 票同意，0 票反对，0 票弃权。 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：8 票同意，0 票反对，0 票弃权。 具体详见 2025 年 4 月 29 日刊登在公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）及《上海证券报》、 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-020 江苏蓝丰生物化工股份有限公司 关于回购注销部分限制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、本次拟回购注销的限制性股票数量为 19,716,300 股，其中本次回购注销 涉及的 2021 年限制性股票 12,838,000 股，回购价格均为 3.00 元/股加上银行同 期存款利息；回购注销涉及的 2024 年限制性股票 6,878,300 股，回购价格均为 1.80 元/股加上银行同期存款利息。 2、回购注销完成后，公司总股本将由 375,280,278 股调整为 355,563,978 股。 3、上述回购注销事项尚需提交公司股东大会审议。 1 对象名单的议案》。 2、2022 年 1 月 4 日至 2022 年 1 月 13 日期间，公司通过张榜方式在公司内 部将激励对象的姓名和职务予以公示。在公示的时限内，监事会未收到任何组织 或个人提出异议或不良反映。2022 年 1 月 14 日，公司披露了《监事会关于公司 2021 年股权激励计划激励对象名单的审 ...

江苏蓝丰生物化工股份有限公司 营业收入扣除情况的专项核查意见 2024 年度 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 中国．江苏．无锡 Wuxi．Jiangsu．China 2024 年度营业收入扣除情况的专项核查意见 苏公W[2025]E1297号 江苏蓝丰生物化工股份有限公司全体股东： 我们接受委托，审计了江苏蓝丰生物化工股份有限公司（以下简称蓝丰生化） 财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并 及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及 相关财务报表附注，并于 2025 年 4 月 27 日出具了苏公 W[2025]A686 号无保留意见 审计报告。在此基础上，我们核查了后附的蓝丰生 ...

北京市万商天勤律师事务所 关于 江苏蓝丰生物化工股份有限公司 2021 年限制性股票激励计划、2024 年限制性股票激 励计划回购注销部分限制性股票的 法律意见书 | 释 义 | 2 | | --- | --- | | 律师声明 | 4 | | 正 文 | 6 | | 年激励计划及 年激励计划的实施情况 一、2021 2024 | 6 | | （一）2021 年激励计划实施的相关批准与授权 | 6 | | （二）2024 年激励计划实施的相关批准与授权 | 8 | | 二、本次回购注销的批准与授权 | 9 | | 三、本次回购注销的具体情况 | 10 | | （一）2021 年激励计划限制性股票回购注销的情况 | 10 | | 1、回购注销的原因 | 10 | | 2、回购注销的数量、价格及定价依据 | 10 | | 3、回购注销的资金总额及资金来源 | 11 | | 年激励计划限制性股票回购注销的情况 （二）2024 | 11 | | 1、回购注销的原因 | 11 | | 2、回购注销的数量、价格及定价依据 | 12 | | 3、回购注销的资金总额及资金来源 | 12 | | 四、结论意见 | 12 | 释 ...

江苏蓝丰生物化工股份有限公司 内部控制审计报告 2024 年度 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 中国 . 江苏 . 无锡 Wuxi . Jiangsu . China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要 求，我们审计了江苏蓝丰生物化工股份有限公司（以下简称"蓝丰生化"） 2024 年 12 月 31 日的财务报告内部控制有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内 部控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效 性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 电子信箱：mail@gztycpa.cn E-mail：mail@g ...

江苏蓝丰生物化工股份有限公司 审计报告 2024 年度 中国 . 江苏 . 无锡 Wuxi . Jiangsu . China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 审计报告 苏公 W[2025]A686 号 江苏蓝丰生物化工股份有限公司全体股东： 一、审计意见 我们审计了江苏蓝丰生物化工股份有限公司（以下简称"蓝丰生化"）的财务报表， 包括2024年12月31日的合并及母公司资产负债表，2024年度的合并及母公司利润表、合 并及母公司现金流量表、合并及母公司所有者权益变动表，以及财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反 映了蓝丰生化2024年12月31日的合并及母公司财务状况以及2024年度的合并及母公司 经营成果和现金流量。 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, ...

江苏蓝丰生物化工股份有限公司 非经营性资金占用及其他关联资金往来情况的专项说明 2024 年度 Gongzheng Tianye Certified Public Accountants, SGP 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa. cn E-mail：mail@gztycpa. cn 关于江苏蓝丰生物化工股份有限公司 非经营性资金占用及其他关联资金往来情况的 专项说明 苏公W[2025]E1293号 苏州蓝丰生化料股份有限公司全体股东： 我们接受委托，按照中国注册会计师审计准则审计了江苏蓝丰生物化工股 份有限公司（以下简称"蓝丰生化"）财务报表，包括 2024 年 12 月 31 日的合并 及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表以及相关财务报表附注，并于 2025 年 4 月 27 日出具了苏公 W[2025]A686 号无保留意见审计报告。 公证天业会计师事务所(特殊普通合伙) ...

Business Focus and Structure - The company reported a significant change in its main business focus, shifting from "pharmaceutical health + pesticide chemicals" to "pesticide chemicals + photovoltaic new energy" after acquiring 51% of Anhui Xuhe Technology New Energy Co., Ltd. in October 2023[20]. - The company has undergone significant changes in its business structure, including the completion of a major asset restructuring involving the acquisition of Fangzhou Pharmaceutical in 2015[20]. - The company has entered the photovoltaic new energy sector through the acquisition of Xuhe Technology, establishing a dual business model of "agriculture + new energy" for future growth[97]. Financial Performance - The company's operating revenue for 2024 was CNY 1,793,141,048.95, representing a 2.96% increase compared to CNY 1,741,628,407.17 in 2023[22]. - The net profit attributable to shareholders for 2024 was a loss of CNY 252,500,773.62, an improvement of 24.01% from a loss of CNY 332,260,445.98 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY 106,181,646.18, a significant increase of 127.70% compared to a negative cash flow of CNY 383,302,095.05 in 2023[22]. - The total assets at the end of 2024 were CNY 3,418,834,199.38, a slight increase of 0.57% from CNY 3,399,589,930.03 at the end of 2023[22]. - The net assets attributable to shareholders increased by 29.01% to CNY 32,536,860.02 at the end of 2024, up from CNY 25,221,286.52 at the end of 2023[22]. - The company reported a basic earnings per share of -CNY 0.6849 for 2024, which is a 23.14% improvement from -CNY 0.8911 in 2023[22]. Market and Industry Trends - The agricultural chemical industry showed a stable growth trend with a 22.2% year-on-year increase in the production of chemical pesticide raw materials in China for 2024[30]. - The company is navigating challenges from geopolitical conflicts and inflation pressures while maintaining a stable operational outlook[30]. - The photovoltaic market is transitioning from policy-driven to demand-driven, with a stable growth outlook for clean energy globally[39]. - The global photovoltaic market is expected to maintain a long-term growth trend, supported by stable policies and increasing demand in emerging markets[39]. Research and Development - The company is focusing on enhancing its core competitiveness through technological innovation and brand building in response to increasing industry uncertainties[30]. - The company is engaged in the research and development of efficient, low-toxicity pesticides, with competitive advantages in early market entry and established production technologies[43]. - The company has a robust R&D system, with over 100 patent applications filed during the reporting period, including 4 invention patents and 25 utility model patents granted[53]. - R&D investment surged to ¥68,680,051.26 in 2024, marking a 350.18% increase from ¥15,256,020.56 in 2023, representing 3.83% of operating revenue[75]. Environmental and Safety Compliance - The company is committed to environmental governance as a prerequisite for development, emphasizing the reduction of various pollutants[160]. - The company has implemented continuous upgrades in technology and equipment to reduce pollutant emissions, focusing on both source control and end-of-pipe treatment[160]. - The company has established a safety management department with 19 dedicated personnel, including 7 registered safety engineers[172]. - The company has completed 47 emergency drills in the reporting period, with no safety production accidents occurring[175]. Corporate Governance and Shareholder Relations - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective shareholder communication and rights[103]. - The company’s board includes independent directors, ensuring governance and oversight[113]. - The company plans to optimize the remuneration structure and strengthen incentive mechanisms to protect the interests of the company and all shareholders[124]. - The company has made commitments to maintain the legitimate rights and interests of all shareholders and will not engage in unfair benefit transfers[180]. Strategic Initiatives and Future Outlook - The company plans to enhance product diversity and competitiveness through the development of new technologies and products, including the TNP bifacial passivated solar cell[75]. - The company aims to increase the annual production capacity of its core product, with a target of 7,000 tons of a specific pesticide by optimizing production scheduling and enhancing operational standards[97]. - The company plans to continue optimizing channel resource allocation and enhancing marketing capabilities for its formulation products to prepare for market recovery[58]. - The company is focusing on market expansion, targeting new regions that could potentially increase market share by DD%[120].

Financial Performance - The company's revenue for Q1 2025 reached ¥543,942,036.72, representing a 43.86% increase compared to ¥378,109,304.42 in the same period last year[5]. - The net loss attributable to shareholders decreased to ¥22,154,823.78, a 27.38% improvement from a loss of ¥30,509,968.18 in the previous year[5]. - The net loss for the current period was ¥36,652,360.38, compared to a net loss of ¥42,479,148.33 in the previous period, indicating an improvement of approximately 13.5%[21]. - The company's weighted average return on equity improved to -98.31% from -275.86% year-on-year, reflecting a significant reduction in losses[5]. - The company reported a basic and diluted earnings per share of -0.0590, an improvement from -0.0825 in the previous period[21]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥131,618,672.70, worsening by 33.39% compared to a negative cash flow of ¥98,675,401.02 last year[5]. - Operating cash inflow for the current period was CNY 593,336,418.54, a slight increase from CNY 587,684,219.51 in the previous period[22]. - Cash inflow from financing activities totaled CNY 204,500,000.00, slightly down from CNY 205,136,621.05 in the previous period[23]. - The ending cash and cash equivalents balance was CNY 72,380,613.54, up from CNY 35,217,795.77 in the previous period[23]. - Cash received from investment activities was CNY 494,920.89, compared to CNY 36,200.00 in the previous period[22]. Assets and Liabilities - Total assets increased by 7.38% to ¥3,670,979,943.29 from ¥3,418,834,199.38 at the end of the previous year[5]. - Total liabilities increased to ¥3,392,534,886.30 from ¥3,106,254,842.30, which is an increase of approximately 9.2%[18]. - The company's total current assets increased to 1,572,989,951.02 yuan from 1,307,554,415.34 yuan, reflecting a growth of approximately 20.3%[16]. - The total equity attributable to shareholders of the parent company decreased to ¥12,532,821.11 from ¥32,536,860.02, a decline of about 61.5%[18]. - The total non-current liabilities amounted to ¥783,068,811.51, a slight increase from ¥773,176,926.83, reflecting a growth of approximately 1.3%[18]. Research and Development - Research and development expenses decreased by 41.43% to ¥15,858,510.05 from ¥27,074,326.90 in the previous year, indicating a reduction in R&D investment[10]. - Research and development expenses for the current period were ¥15,858,510.05, down from ¥27,074,326.90, representing a decrease of approximately 41.4%[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,951[12]. - The largest shareholder, Zheng Xu, holds 17.98% of the shares, totaling 67,457,432 shares, with 50,593,074 shares under lock-up and 33,500,000 shares pledged[12]. - The second-largest shareholder, Hainan Wenqin Private Equity Fund, holds 8.95% of the shares, totaling 33,589,000 shares, with 23,793,411 shares under lock-up[13]. Market and Operational Insights - The company reported a significant increase in sales revenue from photovoltaic cells and components, contributing to the overall revenue growth[10]. - The company is actively exploring market expansion strategies and new product development initiatives[15]. - Total operating costs increased to ¥588,744,587.62 from ¥440,095,408.26, reflecting a rise of about 33.7%[19]. Audit Information - The company did not undergo an audit for the first quarter report[24].